Home › FDA Resources › Drug Shortages

FDA Drug Shortages & Peptides

How drug shortages affect peptide availability and compounding regulations

Note: Drug shortage status changes frequently. Always verify current status on FDA.gov for the most up-to-date information.

Understanding Drug Shortages

A drug shortage occurs when the demand for an FDA-approved drug exceeds supply. This can happen due to manufacturing problems, increased demand, raw material shortages, or business decisions by manufacturers.

Why Shortages Matter for Peptides

Drug shortages have significant implications for peptide access:

  • Compounding Exception: When a drug is on the shortage list, compounding pharmacies may be able to prepare it
  • Patient Access: Shortages can leave patients without needed medications
  • Price Impact: Limited supply can drive up costs
  • Alternative Seeking: Patients may turn to research chemicals or overseas sources

Current Peptide-Related Shortages

Medication Status Compounding Impact
Semaglutide (Ozempic/Wegovy) Check FDA Status determines compounding legality
Tirzepatide (Mounjaro/Zepbound) Check FDA Shortage enabled compounding
Liraglutide (Saxenda) Variable Intermittent availability
Important: Shortage status is dynamic. The table above may not reflect current status. Always check FDA Drug Shortage Database directly.

The GLP-1 Shortage Story

The shortage of GLP-1 receptor agonists has been one of the most significant peptide shortage events:

Timeline

  • 2022: Demand for semaglutide surges due to weight loss popularity
  • 2023: FDA adds semaglutide to shortage list; tirzepatide follows
  • 2023-2024: Compounding pharmacies begin producing GLP-1 medications
  • 2024: FDA takes enforcement action against some compounders
  • Ongoing: Legal battles over compounding rights continue

Impact on Patients

  • Difficulty obtaining prescriptions from pharmacies
  • Insurance coverage challenges
  • Seeking alternatives from compounding pharmacies
  • Some turning to overseas or research sources

Compounding During Shortages

When a drug is listed on the FDA shortage database:

What's Permitted

  • 503A pharmacies may compound with valid prescription
  • 503B facilities may produce for healthcare facilities
  • The "essentially a copy" restriction is waived

What's Still Required

  • Proper pharmacy licensing
  • Quality and safety standards
  • Appropriate sourcing of ingredients
  • Accurate labeling

When Shortage Ends

  • FDA provides notice of shortage resolution
  • Compounders must cease production of copies
  • Transition period may be provided
  • Patients must switch back to commercial product

Other Peptide Shortages

Beyond GLP-1 medications, other peptide-related shortages have occurred:

  • Insulin: Various formulations experience periodic shortages
  • Glucagon: Emergency treatment occasionally in short supply
  • Vasopressin: Critical care medication with historical shortages
  • Octreotide: Used for various conditions, occasional supply issues

How to Check Shortage Status

The FDA maintains an official drug shortage database:

  1. Visit FDA Drug Shortage Database
  2. Search by drug name or active ingredient
  3. Check current status and estimated resolution
  4. Review manufacturer-specific information

What to Do During a Shortage

For Patients

  • Contact your pharmacy about availability
  • Ask your doctor about alternatives
  • Check multiple pharmacies
  • Ask about compounding options if appropriate
  • Do not stop medications without medical guidance

For Healthcare Providers

  • Monitor FDA shortage notifications
  • Identify therapeutic alternatives
  • Consider compounded options when legally permitted
  • Communicate proactively with patients

Recent Developments

  • 2024: Ongoing debates over GLP-1 compounding legality
  • 2024: Manufacturers increasing production capacity
  • 2023: FDA scrutiny of compounding quality